Evidence check: 7 versus 14 days of antibiotics × 28-day symptom recurrence in afebrile men with UTI

Required evidence, verification status and materials actually read
Item	AVerification status	BReading scope	CReview item	DCurrent findings	EWhy unverified	FRequired materials and conditions	GFurther research
1	Partly verified	Full text not readStored summary read	N01 · Efficacy comparison and presentation of stored materialHow does 28-day recurrence differ from the parent symptom-resolution judgment?Required	The selected question is ‘28-day symptom recurrence’, with grade D and the note ‘9.9% versus 12.9%, with a wide CI’. The parent judgment concerns noninferiority of symptom resolution within 14 days after treatment ended, B70 and Caution; the subclaim has no score, status or axes. S01	This is a record from the stored summary. Some information exists in the stored summary, but No new recurrence score or judgment is assigned, and parent values are not inherited. Review of existing content remains incomplete.	Distinguishing the subclaim's D grade and note, absent score, status and axes, from the parent's B70 and axes	A proposal for follow-up materials linking Distinguishing the subclaim's D grade and note, absent score, status and axes, from the parent's B70 and axes as a separate item; no new research, calculation or testing is performed in this preparation.
2	Partly verified	Full text not readStored summary read	N02 · Efficacy comparison and presentation of stored materialWhat are the originally recorded recurrence fractions and rates?Required	The existing Korean counterview records recurrence as 13/131(9.9%) versus 15/123(12.9%). Fractions and parenthetical rates are preserved separately, without division, recalculation or correction to other values. S01	This is a record from the stored summary. Some information exists in the stored summary, but The original result table's fraction and rate definitions, rounding or estimation, and denominator correspondence have not been read externally. Review of existing content remains incomplete.	The original records of 13/131(9.9%) and 15/123(12.9%)	A proposal for follow-up materials linking The original records of 13/131(9.9%) and 15/123(12.9%) as a separate item; no new research, calculation or testing is performed in this preparation.
3	Partly verified	Full text not readStored summary read	N03 · Efficacy comparison and presentation of stored materialWhat estimand does the recurrence difference and its 95% interval represent?Required	The recurrence difference −3.0%p(95% CI −10.8~6.2) is preserved as recorded. No new difference is calculated from the fractions or rates, and the CI is not narrowed to present a definite benefit, absence of harm or equivalence. S01	This is a record from the stored summary. Some information exists in the stored summary, but The exact group contrast, adjustment or model, original P value and threshold for an important recurrence difference remain unverified. Review of existing content remains incomplete.	The original −3.0%p and 95% CI −10.8~6.2, and the direction of comparison	A proposal for follow-up materials linking The original −3.0%p and 95% CI −10.8~6.2, and the direction of comparison as a separate item; no new research, calculation or testing is performed in this preparation.
4	Partly verified	Full text not readStored summary read	N04 · Efficacy comparison and presentation of stored materialWhere does the 28-day observation window begin?Required	The subclaim question and English text concern recurrence at 28 days/by28days. The parent's primary endpoint is symptom resolution within 14 days after treatment ended; these are not converted to the same observation window. S01	This is a record from the stored summary. Some information exists in the stored summary, but The 28-day reference point or assessment day, first or repeated recurrence, and whether recurrence is conditional on symptom resolution remain unverified. Review of existing content remains incomplete.	The existing 28-day timing definition, treatment start or end, and first or repeated recurrence	A proposal for follow-up materials linking The existing 28-day timing definition, treatment start or end, and first or repeated recurrence as a separate item; no new research, calculation or testing is performed in this preparation.
5	Partly verified	Full text not readStored summary read	N05 · Efficacy comparison and presentation of stored materialHow is symptom recurrence defined?Required	The original materials report the rate of symptom recurrence. This is not arbitrarily redefined as measuring microbiological reinfection, same-organism relapse, persistent symptoms or severe events. S01	This is a record from the stored summary. Some information exists in the stored summary, but Symptom and duration thresholds, reporting methods, culture or retreatment, and adjudication rules remain unverified. Review of existing content remains incomplete.	Distinguishing symptom criteria, patient reporting or culture, and a new event after resolution	A proposal for follow-up materials linking Distinguishing symptom criteria, patient reporting or culture, and a new event after resolution as a separate item; no new research, calculation or testing is performed in this preparation.
6	Partly verified	Full text not readStored summary read	N06 · Efficacy comparison and presentation of stored materialHow do the recurrence denominators 131/123 relate to the 272/254 participants?Required	The original records of 272 randomized participants, all with completed follow-up, and the prespecified as-treated analysis of 254 participants (131/123) are preserved. Even though the recurrence denominators are also 131/123, conditions concerning resolved symptoms, assessment populations or the definitions of all actual denominators are not newly filled in. S01	This is a record from the stored summary. Some information exists in the stored summary, but Details of inclusion and exclusion in the recurrence population, initial resolution or observation, adherence and group-specific missingness remain unverified. Review of existing content remains incomplete.	Distinguishing randomized participants, the adherent primary analysis, and the recurrence observation population or missing data	A proposal for follow-up materials linking Distinguishing randomized participants, the adherent primary analysis, and the recurrence observation population or missing data as a separate item; no new research, calculation or testing is performed in this preparation.
7	Partly verified	Full text not readStored summary read	N07 · Efficacy comparison and presentation of stored materialWhat scope do the prespecified adherence criteria have for recurrence?Required	The original primary-analysis criteria selected 254 participants who took at least 26 of 28 doses and missed no more than 2 consecutive doses. These are historical analysis-selection criteria and are not repurposed as dosing instructions or recurrence effects for all randomized participants. S01	This is a record from the stored summary. Some information exists in the stored summary, but Adherence selection or exposure applied to the recurrence analysis, outcomes of nonadherent participants and sensitivity analyses remain unverified. Review of existing content remains incomplete.	The original selection criteria of at least 26 of 28 doses and no more than 2 consecutive missed doses	A proposal for follow-up materials linking The original selection criteria of at least 26 of 28 doses and no more than 2 consecutive missed doses as a separate item; no new research, calculation or testing is performed in this preparation.
8	Unverified	Full text not readStored summary read	N08 · Efficacy comparison and presentation of stored materialAre the consistency-analysis results for all randomized participants recurrence results?Required	The consistency analysis of all 272 participants, 91.9% versus 90.4%, difference +1.5%p and one-sided 97.5% lower bound −5.8, concerns symptom resolution. These values are not transferred to recurrence rates, a 95% interval or a recurrence sensitivity analysis. S01	This is a record from the stored summary. The currently required information remains unverified. Recurrence values, intervals, missingness and plans for all randomized participants remain unverified in the stored summary. Review of existing content remains incomplete.	The separate role of symptom resolution at 91.9/90.4%, +1.5 and the one-sided lower bound −5.8	A proposal for follow-up materials linking The separate role of symptom resolution at 91.9/90.4%, +1.5 and the one-sided lower bound −5.8 as a separate item; no new research, calculation or testing is performed in this preparation.
9	Partly verified	Full text not readStored summary read	N09 · Efficacy comparison and presentation of stored materialDoes the −10%p noninferiority margin for symptom resolution apply to recurrence?Required	The parent's primary analysis records resolution as 122/131(93.1%) versus 111/123(90.2%), +2.9%p, a one-sided 97.5% lower bound −5.2 and margin −10; these define the resolution analysis. Neither the margin nor the noninferiority conclusion is inherited by the two-sided 95% CI for recurrence. S01	This is a record from the stored summary. Some information exists in the stored summary, but The prespecified recurrence margin or important difference, separate power and analysis hierarchy remain unverified. Review of existing content remains incomplete.	Distinguishing the parent's primary-resolution margin and one-sided CI from the two-sided recurrence interval	A proposal for follow-up materials linking Distinguishing the parent's primary-resolution margin and one-sided CI from the two-sided recurrence interval as a separate item; no new research, calculation or testing is performed in this preparation.
10	Partly verified	Full text not readStored summary read	N10 · Efficacy comparison and presentation of stored materialWhat position does recurrence have in the prespecified endpoint hierarchy?Required	The existing evidence list's endpoint and primary analysis concern noninferiority of symptom resolution. The selected 28-day recurrence question is not promoted to a primary endpoint, independent confirmation or a prespecified noninferiority question. S01	This is a record from the stored summary. Some information exists in the stored summary, but The prespecified recurrence hierarchy, multiple comparisons, denominator or timing, and SAP remain unverified. Review of existing content remains incomplete.	The primary symptom-resolution endpoint and prespecification or multiplicity for recurrence	A proposal for follow-up materials linking The primary symptom-resolution endpoint and prespecification or multiplicity for recurrence as a separate item; no new research, calculation or testing is performed in this preparation.
11	Partly verified	Full text not readStored summary read	N11 · Efficacy comparison and presentation of stored materialWhat are the actual population and US VA study conditions?Required	The original study included 272 afebrile men with UTI at two US VA centers. Its existing boundary is preserved: results cannot be directly applied to uncomplicated cystitis in women, febrile UTI, prostatitis or other drugs. S01	This is a record from the stored summary. Some information exists in the stored summary, but Exact ages or comorbidities, inclusion and exclusion criteria, infection or culture conditions, and recurrence risk remain unverified. Review of existing content remains incomplete.	Afebrile men with UTI, two centers, and eligibility or baseline conditions	A proposal for follow-up materials linking Afebrile men with UTI, two centers, and eligibility or baseline conditions as a separate item; no new research, calculation or testing is performed in this preparation.
12	Partly verified	Full text not readStored summary read	N12 · Efficacy comparison and presentation of stored materialWhat historical comparison do 7 versus 14 days and the two antibiotics represent?Required	The comparison of 7 versus 14 days of ciprofloxacin or TMP-SMX is an original study condition. It does not create instructions on drug selection, treatment duration, prescribing or suitability, and equal recurrence effects of the two drugs are not assumed. S01	This is a record from the stored summary. Some information exists in the stored summary, but Drug-specific denominators and recurrence, dose or actual adherence, crossover or retreatment, and concomitant treatment remain unverified. Review of existing content remains incomplete.	The study duration and drugs, placebo, and actual exposure or concomitant treatment	A proposal for follow-up materials linking The study duration and drugs, placebo, and actual exposure or concomitant treatment as a separate item; no new research, calculation or testing is performed in this preparation.
13	Partly verified	Full text not readStored summary read	N13 · Efficacy comparison and presentation of stored materialHas the double-blind, placebo-controlled design been verified through recurrence measurement?Required	The original study is a double-blind, placebo-controlled noninferiority RCT. Recurrence measurement procedures, assessor blinding, participants' actual awareness and the original B1 axis are kept separate. S01	This is a record from the stored summary. Some information exists in the stored summary, but Sequence generation or concealment, recurrence instruments or collection timing, assessors and blinding details remain unverified. Review of existing content remains incomplete.	Allocation or concealment, recurrence collection or assessors, and awareness of assignment	A proposal for follow-up materials linking Allocation or concealment, recurrence collection or assessors, and awareness of assignment as a separate item; no new research, calculation or testing is performed in this preparation.
14	Partly verified	Full text not readStored summary read	N14 · Efficacy comparison and presentation of stored materialAre reports, populations and the sibling resolution question kept from being counted as new replications?Required	The resolution, recurrence and safety values in one Drekonja2021 report, and the parent or sibling questions, are different endpoints or denominators of the same study. They are not added as independent trials, new participants or total events. S01	This is a record from the stored summary. Some information exists in the stored summary, but Unique clinical trial, participant and independent replication totals have not been verified and are not recorded. Review of existing content remains incomplete.	The same Drekonja trial, 272/254 participants, and shared resolution, recurrence and safety results	A proposal for follow-up materials linking The same Drekonja trial, 272/254 participants, and shared resolution, recurrence and safety results as a separate item; no new research, calculation or testing is performed in this preparation.
15	Partly verified	Full text not readStored summary read	N15 · Efficacy comparison and presentation of stored materialIs the 1793 nitrofurantoin article reference a direct recurrence report?Required	The existing cross-citation of 1793 refers to an article on clinical cure of acute uncomplicated cystitis in women, B70. That article or trial has not been read in this preparation, and is not turned into a direct trial or replication of 28-day recurrence in men. S02	This is a record from the stored summary. Some information exists in the stored summary, but The article's actual materials or population and its direct connection to the selected question in men remain unverified. Review of existing content remains incomplete.	The B70 reference for uncomplicated cystitis in women and differences from men or the two drugs	A proposal for follow-up materials linking The B70 reference for uncomplicated cystitis in women and differences from men or the two drugs as a separate item; no new research, calculation or testing is performed in this preparation.
16	Partly verified	Full text not readStored summary read	N16 · Efficacy comparison and presentation of stored materialWhat different question does the 862 fosfomycin article reference concern?Required	The existing cross-citation of 862 refers to an article on single-dose fosfomycin for uncomplicated cystitis in women, B62. Only the relative URL and stored-summary wording are preserved; no new clinical evidence list, antibiotic selection or effect in men is created. S03	This is a record from the stored summary. Some information exists in the stored summary, but The article's full text or trial and direct materials for the selected recurrence conditions have not been read. Review of existing content remains incomplete.	The boundary between B62 single-dose treatment in nonpregnant women and 28-day recurrence in men	A proposal for follow-up materials linking The boundary between B62 single-dose treatment in nonpregnant women and 28-day recurrence in men as a separate item; no new research, calculation or testing is performed in this preparation.
17	Partly verified	Full text not readStored summary read	N17 · Efficacy comparison and presentation of stored materialWhat is the scope of VA support, products, employees and COI?Required	The original VA public funding and the parent's I2 are preserved as historical records. Public funding alone is not taken as evidence about free drugs or placebo, company or employee authors, absence of COI, or an independence certification in this preparation. S01	This is a record from the stored summary. Some information exists in the stored summary, but Details of product support, analysis or writing roles, authors or COI, and contracts remain unverified. Review of existing content remains incomplete.	The US VA Cooperative Studies Program and actual roles or support	A proposal for follow-up materials linking The US VA Cooperative Studies Program and actual roles or support as a separate item; no new research, calculation or testing is performed in this preparation.
18	Partly verified	Full text not readStored summary read	N18 · Efficacy comparison and presentation of stored materialHave the registration and prespecified recurrence plan actually been read?Required	The original NCT01994538 is preserved. The identifier or description of the parent's prespecified analysis is not inherited as actual reading of the registration, protocol or SAP, or as fulfillment of prespecified recurrence conditions. S01	This is a record from the stored summary. Some information exists in the stored summary, but The full registration, change history, recurrence plans or margins, and multiplicity have not been read. Review of existing content remains incomplete.	The NCT01994538 record, recurrence timing, hierarchy and denominator, and SAP	A proposal for follow-up materials linking The NCT01994538 record, recurrence timing, hierarchy and denominator, and SAP as a separate item; no new research, calculation or testing is performed in this preparation.
19	Partly verified	Full text not readStored summary read	N19 · Harm-information gaps supplementing the efficacy tableAre adverse-event denominators and differences a separate outcome from recurrence?Supplementary	The original adverse-event results are 28/136(20.6%) versus 33/136(24.3%), difference −3.7%p; the stored summary historically states that it did not report a significance test. These are not converted to recurrence denominators, a statistical safety benefit or zero harm. S01	This is a record from the stored summary. Some information exists in the stored summary, but Original safety collection or definitions, timing or omissions, CI or P values, and relatedness have not been read externally. Review of existing content remains incomplete.	28/136(20.6%), 33/136(24.3%), −3.7%p and the absence of a reported significance test	A proposal for follow-up materials linking 28/136(20.6%), 33/136(24.3%), −3.7%p and the absence of a reported significance test as a separate item; no new research, calculation or testing is performed in this preparation.
20	Partly verified	Full text not readStored summary read	N20 · Efficacy comparison and presentation of stored materialDoes reduced exposure establish reduced individual resistance or long-term recurrence?Required	The article describes shorter exposure and proof of reduced individual resistance as separate matters. This is not extended to resistant organisms, culture-confirmed recurrence, long-term cure or complete prevention. S01	This is a record from the stored summary. Some information exists in the stored summary, but Direct resistance or microbiological data, long-term recurrence, other harms and subgroup materials remain unverified. Review of existing content remains incomplete.	Distinguishing exposure, resistance or culture, and outcomes beyond 28 days	A proposal for follow-up materials linking Distinguishing exposure, resistance or culture, and outcomes beyond 28 days as a separate item; no new research, calculation or testing is performed in this preparation.
21	Partly verified	Full text not readStored summary read	N21 · Efficacy comparison and presentation of stored materialHow are fractions, rates, differences and Korean or English article expressions preserved?Required	The recurrence fractions, parenthetical rates, difference and CI in the existing Korean article, and the rate or difference wording in the existing English article, are each preserved as recorded. No arithmetic comparison, original-table review, value correction or adjudication of conflicts with new materials is performed. S01	This is a record from the stored summary. Some information exists in the stored summary, but Estimation, denominators and rounding in the original table, and detailed correspondence between languages remain unverified. Review of existing content remains incomplete.	Existing records, unread external original tables, and no calculation or correction	A proposal for follow-up materials linking Existing records, unread external original tables, and no calculation or correction as a separate item; no new research, calculation or testing is performed in this preparation.
22	Partly verified	Full text not readStored summary read	N22 · Efficacy comparison and presentation of stored materialAt what level have the stored summary and external paper or article URLs been read?Required	The entire stored summary was read for preparation and is marked ‘Summary read’. PMID34313686 and the two relative article URLs are preserved; external papers or articles, registration, plans and COI are ‘Unread’. Existing cross-citation verification wording is not inherited as content review in this preparation. S01 S02 S03	This is a record from the stored summary. Some information exists in the stored summary, but External access, link or click testing, and comparison with original texts were not performed. Review of existing content remains incomplete.	The entire stored summary, 1 clinical report and 2 other articles, with external materials unread	A proposal for follow-up materials linking The entire stored summary, 1 clinical report and 2 other articles, with external materials unread as a separate item; no new research, calculation or testing is performed in this preparation.
23	Partly verified	Full text not readStored summary read	N23 · Efficacy comparison and presentation of stored materialAre dates, axes, null or false values, empty correction records and absent scores preserved?Required	The parent's B70/Caution, Korean and English articles, unrecorded precision and false indicators, empty correction and deliberation records, and 2026-08-26 in the entire stored summary are preserved. The selected D grade and note, and absent score, status and axes are not filled with parent values. S01 S02 S03	This is a record from the stored summary. Some information exists in the stored summary, but The historical preparation did not reassess, translate the verdict article, correct it or update external materials. Review of existing content remains incomplete.	The parent's B70, subclaim D, 2026-08-26, existing Korean and English articles, and empty values	A proposal for follow-up materials linking The parent's B70, subclaim D, 2026-08-26, existing Korean and English articles, and empty values as a separate item; no new research, calculation or testing is performed in this preparation.
24	Partly verified	Full text not readStored summary read	N24 · Efficacy comparison and presentation of stored materialHow are condition preservation, case production and content review distinguished?Required	Condition preservation, freezing, application, case production and content review are separate records. Review of the existing content is incomplete; record counts are not totals of unique clinical trials/participants. S01 S02 S03	Record from the stored summary. Some information is in the stored summary. Review of the existing content is incomplete and clinical source material was not newly verified. Review of the existing content remains incomplete.	Records of condition preservation, freezing/application, case preparation and incomplete content review	A proposal for follow-up materials linking Records of condition preservation, freezing/application, case preparation and incomplete content review as a separate item; no new research, calculation or testing is performed in this preparation.

No items match your search or filter.

24 itemsWhat the statuses mean

Assessment scope

Stored-material review date: Not recorded
Original evidence cut-off: 2026-08-26
Scope actually checked: Existing review summaries and stored records of methodological application. Full papers, supplements, registrations, plans and original data were not read.
What the dates mean: This is the date the stored materials were checked, not the date of a new search of the clinical literature.
Population: Distinguishing the scope of 272 randomized participants, 254 in the adherent primary analysis, and recurrence denominators 131/123 in afebrile men with UTI at two US VA centers
Ingredient, formulation and route: The historical comparison of ciprofloxacin/TMP-SMX for 7 versus 14 days; no antibiotic or duration instructions
Dose: Not recorded
Comparator: The 7-versus-14-day strategies, distinguishing resolution noninferiority from the definition, timing and denominators of 28-day recurrence
Measured outcome: The selected 28-day symptom-recurrence record: original 13/131(9.9%) versus 15/123(12.9%), difference −3.0%p(CI −10.8~6.2)
Duration: The original 28-day/by28days question; the observation window's exact reference point remains unverified and is separate from resolution within 14 days after treatment ended
Questions outside this scope: Changing the original recurrence fractions, parenthetical rates, difference or CI through arithmetic comparison, recalculation, correction or adjudication of conflicts with new materials; Filling the 28-day reference point, recurrence definition, resolved-symptom conditions or denominators with information absent from the summary; Repurposing the resolution margin −10%p, one-sided 97.5% CI, primary analysis or all-participant consistency values for recurrence noninferiority, precision or a prespecified hierarchy; Repurposing the recurrence CI as zero effect, equivalence, definite recurrence reduction, complete long-term cure or reduced individual resistance; Calculating new populations, exclusion rates or event counts or rates from the adherent primary analysis of 254/131/123, completed follow-up in 272, or safety denominators 136/136; Repurposing articles 1793/862 in women, their drugs or clinical-cure findings as direct trials, replications or drug-selection evidence for recurrence in men; Repurposing safety counts 28/136 and 33/136, difference −3.7 and the absence of a reported test as statistical benefit, zero risk or recurrence values; Changing original public support, existing cross-citation verification wording or I2 into claims about absence of product support, employees or COI, or an independence or QA certification in this preparation; Extending the study's 7/14 days, two drugs or adherence-selection criteria to antibiotic selection, dosing, dose reduction, individual suitability or treatment instructions; Adding references to the same report, trial, population, group, time point, sibling question or manuscript as new independent trials or total participants; Inheriting the parent score or axes, historical cross-checks, original-paper review or existing cross-citation checks as subclaim values, current content review or external reading; New searches or APIs, numerical calculations, hypothetical values, new effects, CIs or grades, certification of independence, or guidance on antibiotic or vaccine selection, use, suitability or treatment

Evidence and sources

The links below lead to the sources. A link alone does not mean the original source was read or its latest publication status verified.

S01 · Drekonja et al. 2021

PubMed

Material type: Double-blind, placebo-controlled noninferiority RCT
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Recurrence was 13/131(9.9%) versus 15/123(12.9%), difference -3.0%p(95% CI -10.8~6.2). The questions in 1793 nitrofurantoin and 862 fosfomycin concern acute uncomplicated cystitis in women. UTI in men has traditionally been classified as a complicated infection; these results must not be combined with uncomplicated cystitis in women. The original recurrence fractions, rates, −3.0 difference and CI are each recorded unchanged. Parenthetical rates or differences are not recalculated from fractions, and the original table or observation window is not corrected. The women's articles 1793/862 provide other article context and are not direct trials of the selected recurrence question.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 Drekonja2021/PMID34313686 is the same resolution, recurrence and safety report from 272 randomized afebrile men with UTI and 254 in the adherent primary analysis (131/123). The original parent's resolution noninferiority is distinguished from 28-day recurrence and safety denominators 136/136. Original recurrence fractions, parenthetical rates, differences and intervals are preserved as separate records without arithmetic checks, calculation or correction. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null. S02 is an existing cross-citation reference to article 1793 on nitrofurantoin and clinical cure of acute uncomplicated cystitis in women, B70. The linked article or trial has not been read in this preparation; its population, exposure and endpoint differ from 28-day recurrence in afebrile men. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null. S03 is an existing cross-citation reference to article 862 on single-dose fosfomycin for uncomplicated cystitis in nonpregnant women, B62. The linked article or trial has not been read in this preparation; its population, exposure and endpoint differ from 28-day recurrence in afebrile men. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External paper	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Registration material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Protocol	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Statistical analysis plan	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.
Funding, product-support and COI material	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

S02 · 1793 nitrofurantoin × clinical cure of acute uncomplicated cystitis (B 70)

Official source

Material type: Citation-only report; no row in the original review summary's evidence list
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Uncomplicated cystitis in women and UTI in men are different questions. Existing cross-citation verification wording and bibliography are preserved historically; clinical content, judgments or numbers are not transferred as direct values for the selected question.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 Drekonja2021/PMID34313686 is the same resolution, recurrence and safety report from 272 randomized afebrile men with UTI and 254 in the adherent primary analysis (131/123). The original parent's resolution noninferiority is distinguished from 28-day recurrence and safety denominators 136/136. Original recurrence fractions, parenthetical rates, differences and intervals are preserved as separate records without arithmetic checks, calculation or correction. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null. S02 is an existing cross-citation reference to article 1793 on nitrofurantoin and clinical cure of acute uncomplicated cystitis in women, B70. The linked article or trial has not been read in this preparation; its population, exposure and endpoint differ from 28-day recurrence in afebrile men. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null. S03 is an existing cross-citation reference to article 862 on single-dose fosfomycin for uncomplicated cystitis in nonpregnant women, B62. The linked article or trial has not been read in this preparation; its population, exposure and endpoint differ from 28-day recurrence in afebrile men. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External manuscript	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

S03 · 862 single-dose fosfomycin 3 g × acute uncomplicated cystitis in nonpregnant women (B 62)

Official source

Material type: Citation-only report; no row in the original review summary's evidence list
Materials actually read: Summary read; external material unread
Findings recorded in the stored summary: Evidence for single-dose treatment in women is not repurposed for men. Existing cross-citation verification wording and bibliography are preserved historically; clinical content, judgments or numbers are not transferred as direct values for the selected question.
Record level: Outcome wording in the stored summary
Study overlap and independent replication: S01 Drekonja2021/PMID34313686 is the same resolution, recurrence and safety report from 272 randomized afebrile men with UTI and 254 in the adherent primary analysis (131/123). The original parent's resolution noninferiority is distinguished from 28-day recurrence and safety denominators 136/136. Original recurrence fractions, parenthetical rates, differences and intervals are preserved as separate records without arithmetic checks, calculation or correction. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null. S02 is an existing cross-citation reference to article 1793 on nitrofurantoin and clinical cure of acute uncomplicated cystitis in women, B70. The linked article or trial has not been read in this preparation; its population, exposure and endpoint differ from 28-day recurrence in afebrile men. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null. S03 is an existing cross-citation reference to article 862 on single-dose fosfomycin for uncomplicated cystitis in nonpregnant women, B62. The linked article or trial has not been read in this preparation; its population, exposure and endpoint differ from 28-day recurrence in afebrile men. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null.

Public availability, access and reading status by material
Material	Public availability	Access status	Actually read	Notes
Stored summary	Stored file	Stored summary	Summary read	Only the stored JSON summary and bibliography were used for production. This does not constitute external verification or completed content review.
External manuscript	Public availability unverified; only bibliography links preserved	Unread; access not attempted	Not read	No external access or click testing was performed in the original preparation. URLs or registration identifiers alone do not upgrade acquisition/reading status.

Report counts versus independent study counts

S01 Drekonja2021/PMID34313686 is the same resolution, recurrence and safety report from 272 randomized afebrile men with UTI and 254 in the adherent primary analysis (131/123). The original parent's resolution noninferiority is distinguished from 28-day recurrence and safety denominators 136/136. Original recurrence fractions, parenthetical rates, differences and intervals are preserved as separate records without arithmetic checks, calculation or correction. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null. S02 is an existing cross-citation reference to article 1793 on nitrofurantoin and clinical cure of acute uncomplicated cystitis in women, B70. The linked article or trial has not been read in this preparation; its population, exposure and endpoint differ from 28-day recurrence in afebrile men. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null. S03 is an existing cross-citation reference to article 862 on single-dose fosfomycin for uncomplicated cystitis in nonpregnant women, B62. The linked article or trial has not been read in this preparation; its population, exposure and endpoint differ from 28-day recurrence in afebrile men. The same report or population, sibling questions, groups, time points, denominators and article references are not added as new independent trials or participants. Report or material slots are not unique clinical totals; independent totals are null.

Review criteria

Version 1.0 · Criteria record date 2026-10-06. These are Chamgap's own application conditions, informed by the referenced methods. They do not constitute official assessment-tool certification or a new efficacy score.

N01 · How does 28-day recurrence differ from the parent symptom-resolution judgment?

Required materials and conditions: Distinguishing the subclaim's D grade and note, absent score, status and axes, from the parent's B70 and axes
Conditions for verification: Relevant original materials and the scope of analysis for Distinguishing the subclaim's D grade and note, absent score, status and axes, from the parent's B70 and axes must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish Distinguishing the subclaim's D grade and note, absent score, status and axes, from the parent's B70 and axes and connect the selected question's required materials with the available materials.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N02 · What are the originally recorded recurrence fractions and rates?

Required materials and conditions: The original records of 13/131(9.9%) and 15/123(12.9%)
Conditions for verification: Relevant original materials and the scope of analysis for The original records of 13/131(9.9%) and 15/123(12.9%) must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The original records of 13/131(9.9%) and 15/123(12.9%) and connect the selected question's required materials with the available materials.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design

N03 · What estimand does the recurrence difference and its 95% interval represent?

Required materials and conditions: The original −3.0%p and 95% CI −10.8~6.2, and the direction of comparison
Conditions for verification: Relevant original materials and the scope of analysis for The original −3.0%p and 95% CI −10.8~6.2, and the direction of comparison must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The original −3.0%p and 95% CI −10.8~6.2, and the direction of comparison and connect the selected question's required materials with the available materials.
Referenced methods: M08 §8.2.2, M15 §15.3.1; Chamgap's own application; M15 §15.3.1–15.3.3; Chamgap's own application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap's own design

N04 · Where does the 28-day observation window begin?

Required materials and conditions: The existing 28-day timing definition, treatment start or end, and first or repeated recurrence
Conditions for verification: Relevant original materials and the scope of analysis for The existing 28-day timing definition, treatment start or end, and first or repeated recurrence must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The existing 28-day timing definition, treatment start or end, and first or repeated recurrence and connect the selected question's required materials with the available materials.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M04 §4.6.3; our own application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design

N05 · How is symptom recurrence defined?

Required materials and conditions: Distinguishing symptom criteria, patient reporting or culture, and a new event after resolution
Conditions for verification: Relevant original materials and the scope of analysis for Distinguishing symptom criteria, patient reporting or culture, and a new event after resolution must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish Distinguishing symptom criteria, patient reporting or culture, and a new event after resolution and connect the selected question's required materials with the available materials.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M03 §3.2.4; our own application

N06 · How do the recurrence denominators 131/123 relate to the 272/254 participants?

Required materials and conditions: Distinguishing randomized participants, the adherent primary analysis, and the recurrence observation population or missing data
Conditions for verification: Relevant original materials and the scope of analysis for Distinguishing randomized participants, the adherent primary analysis, and the recurrence observation population or missing data must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish Distinguishing randomized participants, the adherent primary analysis, and the recurrence observation population or missing data and connect the selected question's required materials with the available materials.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

N07 · What scope do the prespecified adherence criteria have for recurrence?

Required materials and conditions: The original selection criteria of at least 26 of 28 doses and no more than 2 consecutive missed doses
Conditions for verification: Relevant original materials and the scope of analysis for The original selection criteria of at least 26 of 28 doses and no more than 2 consecutive missed doses must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The original selection criteria of at least 26 of 28 doses and no more than 2 consecutive missed doses and connect the selected question's required materials with the available materials.
Referenced methods: M08 §8.2.2, M15 §15.3.1; our own application; M03 §3.2.3, M08 §8.2.2–8.2.3; our own application

N08 · Are the consistency-analysis results for all randomized participants recurrence results?

Required materials and conditions: The separate role of symptom resolution at 91.9/90.4%, +1.5 and the one-sided lower bound −5.8
Conditions for verification: Relevant original materials and the scope of analysis for The separate role of symptom resolution at 91.9/90.4%, +1.5 and the one-sided lower bound −5.8 must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The separate role of symptom resolution at 91.9/90.4%, +1.5 and the one-sided lower bound −5.8 and connect the selected question's required materials with the available materials.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 §8.2.2, M15 §15.3.1; our own application

N09 · Does the −10%p noninferiority margin for symptom resolution apply to recurrence?

Required materials and conditions: Distinguishing the parent's primary-resolution margin and one-sided CI from the two-sided recurrence interval
Conditions for verification: Relevant original materials and the scope of analysis for Distinguishing the parent's primary-resolution margin and one-sided CI from the two-sided recurrence interval must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish Distinguishing the parent's primary-resolution margin and one-sided CI from the two-sided recurrence interval and connect the selected question's required materials with the available materials.
Referenced methods: M15 §15.3.1–15.3.3; our own application; M08 Table 8.2.a, M04 §4.6.3; our own application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design

N10 · What position does recurrence have in the prespecified endpoint hierarchy?

Required materials and conditions: The primary symptom-resolution endpoint and prespecification or multiplicity for recurrence
Conditions for verification: Relevant original materials and the scope of analysis for The primary symptom-resolution endpoint and prespecification or multiplicity for recurrence must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The primary symptom-resolution endpoint and prespecification or multiplicity for recurrence and connect the selected question's required materials with the available materials.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap's own application

N11 · What are the actual population and US VA study conditions?

Required materials and conditions: Afebrile men with UTI, two centers, and eligibility or baseline conditions
Conditions for verification: Relevant original materials and the scope of analysis for Afebrile men with UTI, two centers, and eligibility or baseline conditions must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish Afebrile men with UTI, two centers, and eligibility or baseline conditions and connect the selected question's required materials with the available materials.
Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap's own design

N12 · What historical comparison do 7 versus 14 days and the two antibiotics represent?

Required materials and conditions: The study duration and drugs, placebo, and actual exposure or concomitant treatment
Conditions for verification: Relevant original materials and the scope of analysis for The study duration and drugs, placebo, and actual exposure or concomitant treatment must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The study duration and drugs, placebo, and actual exposure or concomitant treatment and connect the selected question's required materials with the available materials.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

N13 · Has the double-blind, placebo-controlled design been verified through recurrence measurement?

Required materials and conditions: Allocation or concealment, recurrence collection or assessors, and awareness of assignment
Conditions for verification: Relevant original materials and the scope of analysis for Allocation or concealment, recurrence collection or assessors, and awareness of assignment must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish Allocation or concealment, recurrence collection or assessors, and awareness of assignment and connect the selected question's required materials with the available materials.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

N14 · Are reports, populations and the sibling resolution question kept from being counted as new replications?

Required materials and conditions: The same Drekonja trial, 272/254 participants, and shared resolution, recurrence and safety results
Conditions for verification: Relevant original materials and the scope of analysis for The same Drekonja trial, 272/254 participants, and shared resolution, recurrence and safety results must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The same Drekonja trial, 272/254 participants, and shared resolution, recurrence and safety results and connect the selected question's required materials with the available materials.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

N15 · Is the 1793 nitrofurantoin article reference a direct recurrence report?

Required materials and conditions: The B70 reference for uncomplicated cystitis in women and differences from men or the two drugs
Conditions for verification: Relevant original materials and the scope of analysis for The B70 reference for uncomplicated cystitis in women and differences from men or the two drugs must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The B70 reference for uncomplicated cystitis in women and differences from men or the two drugs and connect the selected question's required materials with the available materials.
Referenced methods: Question clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M03 §3.2.1; detailed population conditions are internally designed

N16 · What different question does the 862 fosfomycin article reference concern?

Required materials and conditions: The boundary between B62 single-dose treatment in nonpregnant women and 28-day recurrence in men
Conditions for verification: Relevant original materials and the scope of analysis for The boundary between B62 single-dose treatment in nonpregnant women and 28-day recurrence in men must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The boundary between B62 single-dose treatment in nonpregnant women and 28-day recurrence in men and connect the selected question's required materials with the available materials.
Referenced methods: Question clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptation are internally designed

N17 · What is the scope of VA support, products, employees and COI?

Required materials and conditions: The US VA Cooperative Studies Program and actual roles or support
Conditions for verification: Relevant original materials and the scope of analysis for The US VA Cooperative Studies Program and actual roles or support must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The US VA Cooperative Studies Program and actual roles or support and connect the selected question's required materials with the available materials.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

N18 · Have the registration and prespecified recurrence plan actually been read?

Required materials and conditions: The NCT01994538 record, recurrence timing, hierarchy and denominator, and SAP
Conditions for verification: Relevant original materials and the scope of analysis for The NCT01994538 record, recurrence timing, hierarchy and denominator, and SAP must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The NCT01994538 record, recurrence timing, hierarchy and denominator, and SAP and connect the selected question's required materials with the available materials.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

N19 · Are adverse-event denominators and differences a separate outcome from recurrence?

Required materials and conditions: 28/136(20.6%), 33/136(24.3%), −3.7%p and the absence of a reported significance test
Conditions for verification: Relevant original materials and the scope of analysis for 28/136(20.6%), 33/136(24.3%), −3.7%p and the absence of a reported significance test must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Supplementary
Application exceptions: Addresses gaps in harm information for the selected recurrence/additional tuberculosis prevention question. Original efficacy, recurrence or safety wording is not used to judge overall safety or generate harm rates or guidance on antibiotic or vaccine selection, use or suitability.
Why this condition is needed: An item prepared to distinguish 28/136(20.6%), 33/136(24.3%), −3.7%p and the absence of a reported significance test and connect the selected question's required materials with the available materials.
Referenced methods: M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Detailed distinctions are Chamgap design; M19 §19.1.2–19.2.4; Chamgap application; Chamgap interpretation boundary. M19 principles are referenced; no official causality tool was run

N20 · Does reduced exposure establish reduced individual resistance or long-term recurrence?

Required materials and conditions: Distinguishing exposure, resistance or culture, and outcomes beyond 28 days
Conditions for verification: Relevant original materials and the scope of analysis for Distinguishing exposure, resistance or culture, and outcomes beyond 28 days must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish Distinguishing exposure, resistance or culture, and outcomes beyond 28 days and connect the selected question's required materials with the available materials.
Referenced methods: M03 §3.2.4; our own extension boundary; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design; M19 §19.1.2–19.2.4; our own application

N21 · How are fractions, rates, differences and Korean or English article expressions preserved?

Required materials and conditions: Existing records, unread external original tables, and no calculation or correction
Conditions for verification: Relevant original materials and the scope of analysis for Existing records, unread external original tables, and no calculation or correction must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish Existing records, unread external original tables, and no calculation or correction and connect the selected question's required materials with the available materials.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and our own design

N22 · At what level have the stored summary and external paper or article URLs been read?

Required materials and conditions: The entire stored summary, 1 clinical report and 2 other articles, with external materials unread
Conditions for verification: Relevant original materials and the scope of analysis for The entire stored summary, 1 clinical report and 2 other articles, with external materials unread must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The entire stored summary, 1 clinical report and 2 other articles, with external materials unread and connect the selected question's required materials with the available materials.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N23 · Are dates, axes, null or false values, empty correction records and absent scores preserved?

Required materials and conditions: The parent's B70, subclaim D, 2026-08-26, existing Korean and English articles, and empty values
Conditions for verification: Relevant original materials and the scope of analysis for The parent's B70, subclaim D, 2026-08-26, existing Korean and English articles, and empty values must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish The parent's B70, subclaim D, 2026-08-26, existing Korean and English articles, and empty values and connect the selected question's required materials with the available materials.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

N24 · How are condition preservation, case production and content review distinguished?

Required materials and conditions: Records of condition preservation, freezing/application, case preparation and incomplete content review
Conditions for verification: Relevant original materials and the scope of analysis for Records of condition preservation, freezing/application, case preparation and incomplete content review must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Requirement and applicability: Required
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Why this condition is needed: An item prepared to distinguish Records of condition preservation, freezing/application, case preparation and incomplete content review and connect the selected question's required materials with the available materials.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Referenced methods and the sections actually reviewed

M03 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13

Referenced principle: Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M04 · Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03

Official methodology · §4.5, §4.6.1–4.6.3, MECIR C42

Referenced principle: Distinguish studies from reports and link them; do not omit a study solely because results are unreported.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M08 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §8.1–8.2.3, Table 8.2.a

Referenced principle: Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M15 · Cochrane Handbook 6.5 (2024), chapter updated 2023-08

Official methodology · §15.2.4, §15.3.1–15.3.3

Referenced principle: Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

M19 · Cochrane Handbook 6.5 (2024), chapter updated 2019-10

Official methodology · §19.1.2, §19.2.1–19.2.4

Referenced principle: Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.
Extent of review: Preserved method HTML copies; no current method-content re-review or official tool execution

What the statuses mean

Met: A state used when required evidence is confirmed after user review. This production does not declare that review complete.
Partly verified: Some information in the stored summary is linked into the table. External comparison/content review is not complete.
Unverified: The article leaves this unverified, or required material is absent from the current stored summary. This is distinct from zero, absence or safety.
Review incomplete: User review pending.
Not reported: Not reported within the stored material actually read; not extended to the entire primary paper.
Inaccessible: Means an actual access failure. Access not attempted here is not assigned this state.
Not applicable: Not used as a substitute for an evidence gap.
Conflicting data: Requires an observed disagreement under the same comparison criteria; not automatically judged in this production.
Insufficient evidence for the conditions: Marks a gap in additional material required by the selected conditions; not a new efficacy grade.

Change history

2026-10-10 · Public page/material version 1.0

Public pages and materials were prepared from the existing 24 items. No new clinical search, verification-status change or scoring was performed.

The stored-material review date (Not recorded) and original evidence cut-off (2026-08-26) were retained unchanged.

Researcher downloads

These materials provide the same evidence, scope and verification status as this page.

View all item details

N01 · How does 28-day recurrence differ from the parent symptom-resolution judgment?

Current findings: The selected question is ‘28-day symptom recurrence’, with grade D and the note ‘9.9% versus 12.9%, with a wide CI’. The parent judgment concerns noninferiority of symptom resolution within 14 days after treatment ended, B70 and Caution; the subclaim has no score, status or axes.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but No new recurrence score or judgment is assigned, and parent values are not inherited. Review of existing content remains incomplete.
Reason for missing information: No new recurrence score or judgment is assigned, and parent values are not inherited.
Required materials and conditions: Distinguishing the subclaim's D grade and note, absent score, status and axes, from the parent's B70 and axes
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for Distinguishing the subclaim's D grade and note, absent score, status and axes, from the parent's B70 and axes.
Further research: A proposal for follow-up materials linking Distinguishing the subclaim's D grade and note, absent score, status and axes, from the parent's B70 and axes as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for Distinguishing the subclaim's D grade and note, absent score, status and axes, from the parent's B70 and axes must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish Distinguishing the subclaim's D grade and note, absent score, status and axes, from the parent's B70 and axes and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01

N02 · What are the originally recorded recurrence fractions and rates?

Current findings: The existing Korean counterview records recurrence as 13/131(9.9%) versus 15/123(12.9%). Fractions and parenthetical rates are preserved separately, without division, recalculation or correction to other values.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but The original result table's fraction and rate definitions, rounding or estimation, and denominator correspondence have not been read externally. Review of existing content remains incomplete.
Reason for missing information: The original result table's fraction and rate definitions, rounding or estimation, and denominator correspondence have not been read externally.
Required materials and conditions: The original records of 13/131(9.9%) and 15/123(12.9%)
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The original records of 13/131(9.9%) and 15/123(12.9%).
Further research: A proposal for follow-up materials linking The original records of 13/131(9.9%) and 15/123(12.9%) as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The original records of 13/131(9.9%) and 15/123(12.9%) must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The original records of 13/131(9.9%) and 15/123(12.9%) and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are our own design

Related sources S01

N03 · What estimand does the recurrence difference and its 95% interval represent?

Current findings: The recurrence difference −3.0%p(95% CI −10.8~6.2) is preserved as recorded. No new difference is calculated from the fractions or rates, and the CI is not narrowed to present a definite benefit, absence of harm or equivalence.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but The exact group contrast, adjustment or model, original P value and threshold for an important recurrence difference remain unverified. Review of existing content remains incomplete.
Reason for missing information: The exact group contrast, adjustment or model, original P value and threshold for an important recurrence difference remain unverified.
Required materials and conditions: The original −3.0%p and 95% CI −10.8~6.2, and the direction of comparison
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The original −3.0%p and 95% CI −10.8~6.2, and the direction of comparison.
Further research: A proposal for follow-up materials linking The original −3.0%p and 95% CI −10.8~6.2, and the direction of comparison as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The original −3.0%p and 95% CI −10.8~6.2, and the direction of comparison must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The original −3.0%p and 95% CI −10.8~6.2, and the direction of comparison and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.2.2, M15 §15.3.1; Chamgap's own application; M15 §15.3.1–15.3.3; Chamgap's own application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are Chamgap's own design

Related sources S01

N04 · Where does the 28-day observation window begin?

Current findings: The subclaim question and English text concern recurrence at 28 days/by28days. The parent's primary endpoint is symptom resolution within 14 days after treatment ended; these are not converted to the same observation window.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but The 28-day reference point or assessment day, first or repeated recurrence, and whether recurrence is conditional on symptom resolution remain unverified. Review of existing content remains incomplete.
Reason for missing information: The 28-day reference point or assessment day, first or repeated recurrence, and whether recurrence is conditional on symptom resolution remain unverified.
Required materials and conditions: The existing 28-day timing definition, treatment start or end, and first or repeated recurrence
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The existing 28-day timing definition, treatment start or end, and first or repeated recurrence.
Further research: A proposal for follow-up materials linking The existing 28-day timing definition, treatment start or end, and first or repeated recurrence as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The existing 28-day timing definition, treatment start or end, and first or repeated recurrence must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The existing 28-day timing definition, treatment start or end, and first or repeated recurrence and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M04 §4.6.3; our own application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design

Related sources S01

N05 · How is symptom recurrence defined?

Current findings: The original materials report the rate of symptom recurrence. This is not arbitrarily redefined as measuring microbiological reinfection, same-organism relapse, persistent symptoms or severe events.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Symptom and duration thresholds, reporting methods, culture or retreatment, and adjudication rules remain unverified. Review of existing content remains incomplete.
Reason for missing information: Symptom and duration thresholds, reporting methods, culture or retreatment, and adjudication rules remain unverified.
Required materials and conditions: Distinguishing symptom criteria, patient reporting or culture, and a new event after resolution
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for Distinguishing symptom criteria, patient reporting or culture, and a new event after resolution.
Further research: A proposal for follow-up materials linking Distinguishing symptom criteria, patient reporting or culture, and a new event after resolution as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for Distinguishing symptom criteria, patient reporting or culture, and a new event after resolution must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish Distinguishing symptom criteria, patient reporting or culture, and a new event after resolution and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 Table 8.2.a, M03 §3.2.4; our own application

Related sources S01

N06 · How do the recurrence denominators 131/123 relate to the 272/254 participants?

Current findings: The original records of 272 randomized participants, all with completed follow-up, and the prespecified as-treated analysis of 254 participants (131/123) are preserved. Even though the recurrence denominators are also 131/123, conditions concerning resolved symptoms, assessment populations or the definitions of all actual denominators are not newly filled in.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Details of inclusion and exclusion in the recurrence population, initial resolution or observation, adherence and group-specific missingness remain unverified. Review of existing content remains incomplete.
Reason for missing information: Details of inclusion and exclusion in the recurrence population, initial resolution or observation, adherence and group-specific missingness remain unverified.
Required materials and conditions: Distinguishing randomized participants, the adherent primary analysis, and the recurrence observation population or missing data
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for Distinguishing randomized participants, the adherent primary analysis, and the recurrence observation population or missing data.
Further research: A proposal for follow-up materials linking Distinguishing randomized participants, the adherent primary analysis, and the recurrence observation population or missing data as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for Distinguishing randomized participants, the adherent primary analysis, and the recurrence observation population or missing data must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish Distinguishing randomized participants, the adherent primary analysis, and the recurrence observation population or missing data and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M15 §15.3 and M19 §19.1.2–19.2.4; Design-specific adaptation is Chamgap design; M08 §8.2.2 and M15 §15.3.1; Chamgap application

Related sources S01

N07 · What scope do the prespecified adherence criteria have for recurrence?

Current findings: The original primary-analysis criteria selected 254 participants who took at least 26 of 28 doses and missed no more than 2 consecutive doses. These are historical analysis-selection criteria and are not repurposed as dosing instructions or recurrence effects for all randomized participants.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Adherence selection or exposure applied to the recurrence analysis, outcomes of nonadherent participants and sensitivity analyses remain unverified. Review of existing content remains incomplete.
Reason for missing information: Adherence selection or exposure applied to the recurrence analysis, outcomes of nonadherent participants and sensitivity analyses remain unverified.
Required materials and conditions: The original selection criteria of at least 26 of 28 doses and no more than 2 consecutive missed doses
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The original selection criteria of at least 26 of 28 doses and no more than 2 consecutive missed doses.
Further research: A proposal for follow-up materials linking The original selection criteria of at least 26 of 28 doses and no more than 2 consecutive missed doses as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The original selection criteria of at least 26 of 28 doses and no more than 2 consecutive missed doses must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The original selection criteria of at least 26 of 28 doses and no more than 2 consecutive missed doses and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.2.2, M15 §15.3.1; our own application; M03 §3.2.3, M08 §8.2.2–8.2.3; our own application

Related sources S01

N08 · Are the consistency-analysis results for all randomized participants recurrence results?

Current findings: The consistency analysis of all 272 participants, 91.9% versus 90.4%, difference +1.5%p and one-sided 97.5% lower bound −5.8, concerns symptom resolution. These values are not transferred to recurrence rates, a 95% interval or a recurrence sensitivity analysis.
Verification status: Unverified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. The currently required information remains unverified. Recurrence values, intervals, missingness and plans for all randomized participants remain unverified in the stored summary. Review of existing content remains incomplete.
Reason for missing information: Recurrence values, intervals, missingness and plans for all randomized participants remain unverified in the stored summary.
Required materials and conditions: The separate role of symptom resolution at 91.9/90.4%, +1.5 and the one-sided lower bound −5.8
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The separate role of symptom resolution at 91.9/90.4%, +1.5 and the one-sided lower bound −5.8.
Further research: A proposal for follow-up materials linking The separate role of symptom resolution at 91.9/90.4%, +1.5 and the one-sided lower bound −5.8 as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The separate role of symptom resolution at 91.9/90.4%, +1.5 and the one-sided lower bound −5.8 must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The separate role of symptom resolution at 91.9/90.4%, +1.5 and the one-sided lower bound −5.8 and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M08 §8.2.2, M15 §15.3.1; our own application

Related sources S01

N09 · Does the −10%p noninferiority margin for symptom resolution apply to recurrence?

Current findings: The parent's primary analysis records resolution as 122/131(93.1%) versus 111/123(90.2%), +2.9%p, a one-sided 97.5% lower bound −5.2 and margin −10; these define the resolution analysis. Neither the margin nor the noninferiority conclusion is inherited by the two-sided 95% CI for recurrence.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but The prespecified recurrence margin or important difference, separate power and analysis hierarchy remain unverified. Review of existing content remains incomplete.
Reason for missing information: The prespecified recurrence margin or important difference, separate power and analysis hierarchy remain unverified.
Required materials and conditions: Distinguishing the parent's primary-resolution margin and one-sided CI from the two-sided recurrence interval
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for Distinguishing the parent's primary-resolution margin and one-sided CI from the two-sided recurrence interval.
Further research: A proposal for follow-up materials linking Distinguishing the parent's primary-resolution margin and one-sided CI from the two-sided recurrence interval as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for Distinguishing the parent's primary-resolution margin and one-sided CI from the two-sided recurrence interval must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish Distinguishing the parent's primary-resolution margin and one-sided CI from the two-sided recurrence interval and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M15 §15.3.1–15.3.3; our own application; M08 Table 8.2.a, M04 §4.6.3; our own application; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design

Related sources S01

N10 · What position does recurrence have in the prespecified endpoint hierarchy?

Current findings: The existing evidence list's endpoint and primary analysis concern noninferiority of symptom resolution. The selected 28-day recurrence question is not promoted to a primary endpoint, independent confirmation or a prespecified noninferiority question.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but The prespecified recurrence hierarchy, multiple comparisons, denominator or timing, and SAP remain unverified. Review of existing content remains incomplete.
Reason for missing information: The prespecified recurrence hierarchy, multiple comparisons, denominator or timing, and SAP remain unverified.
Required materials and conditions: The primary symptom-resolution endpoint and prespecification or multiplicity for recurrence
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The primary symptom-resolution endpoint and prespecification or multiplicity for recurrence.
Further research: A proposal for follow-up materials linking The primary symptom-resolution endpoint and prespecification or multiplicity for recurrence as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The primary symptom-resolution endpoint and prespecification or multiplicity for recurrence must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The primary symptom-resolution endpoint and prespecification or multiplicity for recurrence and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 Table 8.2.a, M04 §4.6.3; Chamgap's own application

Related sources S01

N11 · What are the actual population and US VA study conditions?

Current findings: The original study included 272 afebrile men with UTI at two US VA centers. Its existing boundary is preserved: results cannot be directly applied to uncomplicated cystitis in women, febrile UTI, prostatitis or other drugs.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Exact ages or comorbidities, inclusion and exclusion criteria, infection or culture conditions, and recurrence risk remain unverified. Review of existing content remains incomplete.
Reason for missing information: Exact ages or comorbidities, inclusion and exclusion criteria, infection or culture conditions, and recurrence risk remain unverified.
Required materials and conditions: Afebrile men with UTI, two centers, and eligibility or baseline conditions
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for Afebrile men with UTI, two centers, and eligibility or baseline conditions.
Further research: A proposal for follow-up materials linking Afebrile men with UTI, two centers, and eligibility or baseline conditions as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for Afebrile men with UTI, two centers, and eligibility or baseline conditions must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish Afebrile men with UTI, two centers, and eligibility or baseline conditions and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.1; detailed population conditions are Chamgap's own design

Related sources S01

N12 · What historical comparison do 7 versus 14 days and the two antibiotics represent?

Current findings: The comparison of 7 versus 14 days of ciprofloxacin or TMP-SMX is an original study condition. It does not create instructions on drug selection, treatment duration, prescribing or suitability, and equal recurrence effects of the two drugs are not assumed.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Drug-specific denominators and recurrence, dose or actual adherence, crossover or retreatment, and concomitant treatment remain unverified. Review of existing content remains incomplete.
Reason for missing information: Drug-specific denominators and recurrence, dose or actual adherence, crossover or retreatment, and concomitant treatment remain unverified.
Required materials and conditions: The study duration and drugs, placebo, and actual exposure or concomitant treatment
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The study duration and drugs, placebo, and actual exposure or concomitant treatment.
Further research: A proposal for follow-up materials linking The study duration and drugs, placebo, and actual exposure or concomitant treatment as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The study duration and drugs, placebo, and actual exposure or concomitant treatment must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The study duration and drugs, placebo, and actual exposure or concomitant treatment and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.2–3.2.3; reverse-direction labels and checking adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are internally designed

Related sources S01

N13 · Has the double-blind, placebo-controlled design been verified through recurrence measurement?

Current findings: The original study is a double-blind, placebo-controlled noninferiority RCT. Recurrence measurement procedures, assessor blinding, participants' actual awareness and the original B1 axis are kept separate.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Sequence generation or concealment, recurrence instruments or collection timing, assessors and blinding details remain unverified. Review of existing content remains incomplete.
Reason for missing information: Sequence generation or concealment, recurrence instruments or collection timing, assessors and blinding details remain unverified.
Required materials and conditions: Allocation or concealment, recurrence collection or assessors, and awareness of assignment
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for Allocation or concealment, recurrence collection or assessors, and awareness of assignment.
Further research: A proposal for follow-up materials linking Allocation or concealment, recurrence collection or assessors, and awareness of assignment as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for Allocation or concealment, recurrence collection or assessors, and awareness of assignment must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish Allocation or concealment, recurrence collection or assessors, and awareness of assignment and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M08 §8.1–8.2.3; internal application; M08 Table 8.2.a, M03 §3.2.4; internal application

Related sources S01

N14 · Are reports, populations and the sibling resolution question kept from being counted as new replications?

Current findings: The resolution, recurrence and safety values in one Drekonja2021 report, and the parent or sibling questions, are different endpoints or denominators of the same study. They are not added as independent trials, new participants or total events.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Unique clinical trial, participant and independent replication totals have not been verified and are not recorded. Review of existing content remains incomplete.
Reason for missing information: Unique clinical trial, participant and independent replication totals have not been verified and are not recorded.
Required materials and conditions: The same Drekonja trial, 272/254 participants, and shared resolution, recurrence and safety results
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The same Drekonja trial, 272/254 participants, and shared resolution, recurrence and safety results.
Further research: A proposal for follow-up materials linking The same Drekonja trial, 272/254 participants, and shared resolution, recurrence and safety results as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The same Drekonja trial, 272/254 participants, and shared resolution, recurrence and safety results must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The same Drekonja trial, 272/254 participants, and shared resolution, recurrence and safety results and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Study/report distinction in M04 §4.6.1–4.6.2; Cohort/outcome linkage is Chamgap application; M04 §4.6.1–4.6.2 and M15 §15.3.1; Chamgap application

Related sources S01

N15 · Is the 1793 nitrofurantoin article reference a direct recurrence report?

Current findings: The existing cross-citation of 1793 refers to an article on clinical cure of acute uncomplicated cystitis in women, B70. That article or trial has not been read in this preparation, and is not turned into a direct trial or replication of 28-day recurrence in men.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but The article's actual materials or population and its direct connection to the selected question in men remain unverified. Review of existing content remains incomplete.
Reason for missing information: The article's actual materials or population and its direct connection to the selected question in men remain unverified.
Required materials and conditions: The B70 reference for uncomplicated cystitis in women and differences from men or the two drugs
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The B70 reference for uncomplicated cystitis in women and differences from men or the two drugs.
Further research: A proposal for follow-up materials linking The B70 reference for uncomplicated cystitis in women and differences from men or the two drugs as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The B70 reference for uncomplicated cystitis in women and differences from men or the two drugs must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The B70 reference for uncomplicated cystitis in women and differences from men or the two drugs and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Question clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M03 §3.2.1; detailed population conditions are internally designed

Related sources S02

N16 · What different question does the 862 fosfomycin article reference concern?

Current findings: The existing cross-citation of 862 refers to an article on single-dose fosfomycin for uncomplicated cystitis in women, B62. Only the relative URL and stored-summary wording are preserved; no new clinical evidence list, antibiotic selection or effect in men is created.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but The article's full text or trial and direct materials for the selected recurrence conditions have not been read. Review of existing content remains incomplete.
Reason for missing information: The article's full text or trial and direct materials for the selected recurrence conditions have not been read.
Required materials and conditions: The boundary between B62 single-dose treatment in nonpregnant women and 28-day recurrence in men
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The boundary between B62 single-dose treatment in nonpregnant women and 28-day recurrence in men.
Further research: A proposal for follow-up materials linking The boundary between B62 single-dose treatment in nonpregnant women and 28-day recurrence in men as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The boundary between B62 single-dose treatment in nonpregnant women and 28-day recurrence in men must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The boundary between B62 single-dose treatment in nonpregnant women and 28-day recurrence in men and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Question clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application; M03 §3.2.2–3.2.3; reverse-direction labels and test adaptation are internally designed

Related sources S03

N17 · What is the scope of VA support, products, employees and COI?

Current findings: The original VA public funding and the parent's I2 are preserved as historical records. Public funding alone is not taken as evidence about free drugs or placebo, company or employee authors, absence of COI, or an independence certification in this preparation.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Details of product support, analysis or writing roles, authors or COI, and contracts remain unverified. Review of existing content remains incomplete.
Reason for missing information: Details of product support, analysis or writing roles, authors or COI, and contracts remain unverified.
Required materials and conditions: The US VA Cooperative Studies Program and actual roles or support
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The US VA Cooperative Studies Program and actual roles or support.
Further research: A proposal for follow-up materials linking The US VA Cooperative Studies Program and actual roles or support as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The US VA Cooperative Studies Program and actual roles or support must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The US VA Cooperative Studies Program and actual roles or support and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: Chamgap's own conditions for independence and attribution. The official methodological sections used in this example do not validate every detail of these items.

Related sources S01

N18 · Have the registration and prespecified recurrence plan actually been read?

Current findings: The original NCT01994538 is preserved. The identifier or description of the parent's prespecified analysis is not inherited as actual reading of the registration, protocol or SAP, or as fulfillment of prespecified recurrence conditions.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but The full registration, change history, recurrence plans or margins, and multiplicity have not been read. Review of existing content remains incomplete.
Reason for missing information: The full registration, change history, recurrence plans or margins, and multiplicity have not been read.
Required materials and conditions: The NCT01994538 record, recurrence timing, hierarchy and denominator, and SAP
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The NCT01994538 record, recurrence timing, hierarchy and denominator, and SAP.
Further research: A proposal for follow-up materials linking The NCT01994538 record, recurrence timing, hierarchy and denominator, and SAP as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The NCT01994538 record, recurrence timing, hierarchy and denominator, and SAP must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The NCT01994538 record, recurrence timing, hierarchy and denominator, and SAP and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application

Related sources S01

N19 · Are adverse-event denominators and differences a separate outcome from recurrence?

Current findings: The original adverse-event results are 28/136(20.6%) versus 33/136(24.3%), difference −3.7%p; the stored summary historically states that it did not report a significance test. These are not converted to recurrence denominators, a statistical safety benefit or zero harm.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Original safety collection or definitions, timing or omissions, CI or P values, and relatedness have not been read externally. Review of existing content remains incomplete.
Reason for missing information: Original safety collection or definitions, timing or omissions, CI or P values, and relatedness have not been read externally.
Required materials and conditions: 28/136(20.6%), 33/136(24.3%), −3.7%p and the absence of a reported significance test
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for 28/136(20.6%), 33/136(24.3%), −3.7%p and the absence of a reported significance test.
Further research: A proposal for follow-up materials linking 28/136(20.6%), 33/136(24.3%), −3.7%p and the absence of a reported significance test as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for 28/136(20.6%), 33/136(24.3%), −3.7%p and the absence of a reported significance test must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish 28/136(20.6%), 33/136(24.3%), −3.7%p and the absence of a reported significance test and connect the selected question's required materials with the available materials.
Application exceptions: Addresses gaps in harm information for the selected recurrence/additional tuberculosis prevention question. Original efficacy, recurrence or safety wording is not used to judge overall safety or generate harm rates or guidance on antibiotic or vaccine selection, use or suitability.
Referenced methods: M19 §19.1.2–19.2.4; Chamgap application; M19 §19.1.2–19.2.4; Detailed distinctions are Chamgap design; M19 §19.1.2–19.2.4; Chamgap application; Chamgap interpretation boundary. M19 principles are referenced; no official causality tool was run

Related sources S01

N20 · Does reduced exposure establish reduced individual resistance or long-term recurrence?

Current findings: The article describes shorter exposure and proof of reduced individual resistance as separate matters. This is not extended to resistant organisms, culture-confirmed recurrence, long-term cure or complete prevention.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Direct resistance or microbiological data, long-term recurrence, other harms and subgroup materials remain unverified. Review of existing content remains incomplete.
Reason for missing information: Direct resistance or microbiological data, long-term recurrence, other harms and subgroup materials remain unverified.
Required materials and conditions: Distinguishing exposure, resistance or culture, and outcomes beyond 28 days
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for Distinguishing exposure, resistance or culture, and outcomes beyond 28 days.
Further research: A proposal for follow-up materials linking Distinguishing exposure, resistance or culture, and outcomes beyond 28 days as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for Distinguishing exposure, resistance or culture, and outcomes beyond 28 days must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish Distinguishing exposure, resistance or culture, and outcomes beyond 28 days and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4; our own extension boundary; M03 §3.2.1–3.2.4; dose, duration and effect-modification details are our own design; M19 §19.1.2–19.2.4; our own application

Related sources S01

N21 · How are fractions, rates, differences and Korean or English article expressions preserved?

Current findings: The recurrence fractions, parenthetical rates, difference and CI in the existing Korean article, and the rate or difference wording in the existing English article, are each preserved as recorded. No arithmetic comparison, original-table review, value correction or adjudication of conflicts with new materials is performed.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but Estimation, denominators and rounding in the original table, and detailed correspondence between languages remain unverified. Review of existing content remains incomplete.
Reason for missing information: Estimation, denominators and rounding in the original table, and detailed correspondence between languages remain unverified.
Required materials and conditions: Existing records, unread external original tables, and no calculation or correction
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for Existing records, unread external original tables, and no calculation or correction.
Further research: A proposal for follow-up materials linking Existing records, unread external original tables, and no calculation or correction as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for Existing records, unread external original tables, and no calculation or correction must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish Existing records, unread external original tables, and no calculation or correction and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are our own design; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and our own design

Related sources S01

N22 · At what level have the stored summary and external paper or article URLs been read?

Current findings: The entire stored summary was read for preparation and is marked ‘Summary read’. PMID34313686 and the two relative article URLs are preserved; external papers or articles, registration, plans and COI are ‘Unread’. Existing cross-citation verification wording is not inherited as content review in this preparation.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but External access, link or click testing, and comparison with original texts were not performed. Review of existing content remains incomplete.
Reason for missing information: External access, link or click testing, and comparison with original texts were not performed.
Required materials and conditions: The entire stored summary, 1 clinical report and 2 other articles, with external materials unread
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The entire stored summary, 1 clinical report and 2 other articles, with external materials unread.
Further research: A proposal for follow-up materials linking The entire stored summary, 1 clinical report and 2 other articles, with external materials unread as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The entire stored summary, 1 clinical report and 2 other articles, with external materials unread must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The entire stored summary, 1 clinical report and 2 other articles, with external materials unread and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02 S03

N23 · Are dates, axes, null or false values, empty correction records and absent scores preserved?

Current findings: The parent's B70/Caution, Korean and English articles, unrecorded precision and false indicators, empty correction and deliberation records, and 2026-08-26 in the entire stored summary are preserved. The selected D grade and note, and absent score, status and axes are not filled with parent values.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: This is a record from the stored summary. Some information exists in the stored summary, but The historical preparation did not reassess, translate the verdict article, correct it or update external materials. Review of existing content remains incomplete.
Reason for missing information: The historical preparation did not reassess, translate the verdict article, correct it or update external materials.
Required materials and conditions: The parent's B70, subclaim D, 2026-08-26, existing Korean and English articles, and empty values
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for The parent's B70, subclaim D, 2026-08-26, existing Korean and English articles, and empty values.
Further research: A proposal for follow-up materials linking The parent's B70, subclaim D, 2026-08-26, existing Korean and English articles, and empty values as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for The parent's B70, subclaim D, 2026-08-26, existing Korean and English articles, and empty values must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish The parent's B70, subclaim D, 2026-08-26, existing Korean and English articles, and empty values and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M03 §3.1, §3.2.1–3.2.4 question-clarification principles; detailed separation rules are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02 S03

N24 · How are condition preservation, case production and content review distinguished?

Current findings: Condition preservation, freezing, application, case production and content review are separate records. Review of the existing content is incomplete; record counts are not totals of unique clinical trials/participants.
Verification status: Partly verified
Materials actually read: Summary read; external material unread
Why unverified: Record from the stored summary. Some information is in the stored summary. Review of the existing content is incomplete and clinical source material was not newly verified. Review of the existing content remains incomplete.
Reason for missing information: Review of the existing content is incomplete and clinical source material was not newly verified.
Required materials and conditions: Records of condition preservation, freezing/application, case preparation and incomplete content review
Materials to obtain first: Original definitions, result tables or planning materials, or user-provided copies, for Records of condition preservation, freezing/application, case preparation and incomplete content review.
Further research: A proposal for follow-up materials linking Records of condition preservation, freezing/application, case preparation and incomplete content review as a separate item; no new research, calculation or testing is performed in this preparation.
Remaining uncertainty: This preparation links preserved wording; it does not complete comparison with external original papers, an efficacy judgment or content review.
Conditions for verification: Relevant original materials and the scope of analysis for Records of condition preservation, freezing/application, case preparation and incomplete content review must be provided, with unverified matters distinguished. This preparation links wording in the stored summary; review of existing content remains incomplete.
Why this condition is needed: An item prepared to distinguish Records of condition preservation, freezing/application, case preparation and incomplete content review and connect the selected question's required materials with the available materials.
Application exceptions: Limited to the stored summary for the selected formulation, population, endpoint and period. It does not substitute for numbers from other formulations/trials/endpoints or unread external material.
Referenced methods: M04 §4.5–4.6 material collection/selection principles; acquisition/reading separation and hyperlink specifications are internally designed; M04 §4.5, §4.6.3; limits of this material conversion follow the review scope and internal design

Related sources S01 S02 S03